Seres Therapeutics (MCRB) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to -$47.6 million.
- Seres Therapeutics' Enterprise Value rose 2871.12% to -$47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$47.6 million, marking a year-over-year increase of 2871.12%. This contributed to the annual value of -$30.8 million for FY2024, which is 7593.64% up from last year.
- Latest data reveals that Seres Therapeutics reported Enterprise Value of -$47.6 million as of Q3 2025, which was up 2871.12% from -$45.4 million recorded in Q2 2025.
- In the past 5 years, Seres Therapeutics' Enterprise Value ranged from a high of -$30.8 million in Q4 2024 and a low of -$473.1 million during Q3 2021
- For the 5-year period, Seres Therapeutics' Enterprise Value averaged around -$194.6 million, with its median value being -$169.9 million (2023).
- In the last 5 years, Seres Therapeutics' Enterprise Value crashed by 49761.1% in 2021 and then surged by 7593.64% in 2024.
- Seres Therapeutics' Enterprise Value (Quarter) stood at -$290.7 million in 2021, then soared by 37.62% to -$181.3 million in 2022, then grew by 29.43% to -$128.0 million in 2023, then surged by 75.94% to -$30.8 million in 2024, then plummeted by 54.7% to -$47.6 million in 2025.
- Its Enterprise Value stands at -$47.6 million for Q3 2025, versus -$45.4 million for Q2 2025 and -$58.8 million for Q1 2025.